A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

Clinical trial NCT06322095 · UNKNOWN

Trial details

NCT number: NCT06322095
Sponsor: Suzhou Genhouse Bio Co., Ltd.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Patients With Advanced Solid Tumor Advanced Solid Tumor With Oncogenic Driver Mutations

Start date: 2024-03-22
Primary completion: 2025-09-30
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.